Financials
Financial year 2025
DEPHARM from Wavre, company number BE0445912760, closed financial year 2025 with a result of € 122,905 after tax. For that financial year DEPHARM recorded revenue of € 1.2 million and equity of € 25.3 million. Compared with financial year 2024, the result moved from € 71,767 to € 122,905. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ 25.3 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 122,905
▲ 71% vs 2024
Profit after tax over the fiscal year.
€ 116,379
▲ 187% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 23.8 million.
People and assets in 2025
13.6
▼ 0.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.7 million
€ 122,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 444,101
▲ 34% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 88 days on average.
€ 364,405
▲ 24% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 1,068,827 | € 1,225,344 | € 1,165,809 | € 1,244,074 | ▲ 7% |
| Profit after taxes | € -479,218 | € 21,606,419 | € 71,767 | € 122,905 | ▲ 71% |
| Equity | € 4,080,723 | € 25,107,142 | € 25,178,909 | € 25,301,814 | |
| Total debts | € 23,325,141 | € 2,186,158 | € 1,173,700 | € 1,449,389 | ▲ 23% |
| Cash | € 155,350 | € 211,697 | € 40,547 | € 116,379 | ▲ 187% |
| Land & buildings | - | - | - | € 1,510,119 | |
| Retained profit | € 1,984,283 | € 23,590,702 | € 23,662,469 | € 23,785,374 | ▲ 1% |
| Balance sheet total | € 27,405,864 | € 27,293,300 | € 26,352,610 | € 26,751,203 | ▲ 2% |
| Employees (FTE) | 13.6 | 14.5 | 14.5 | 13.6 | ▼ 0.9 |
Key figures of DEPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to DEPHARM?
What happened at DEPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 122,905 (▲ 71% vs 2024). Source: NBB ↗
- MAGILITY SRL became a director. NBB
- New establishment in Wavre. KBO
- New establishment in Wavre. KBO
- Start of the company according to the CBE. KBO
In short
From € 479,218 loss in 2022 to € 122,905 profit in 2025.
Paid € 34,279 in corporate taxes since 2022.
Best year ever: 2023, with € 21.6 million profit.
Pays suppliers within 88 days on average.
A new publication or filing at DEPHARM? We notify you, reason included.
Follow DEPHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind DEPHARM is MAGILITY SRL. It owns 100% of WILL PHARMA BV, 100% of WILL-PHARMA , 100% of LF WILL et CIE and 99.6% of WILL PHARMA LUXEMBOURG itself.
Directors
According to the 2025 annual accounts
since 2024
Establishments
Establishment units
Physical locations of this company
Rue du Manil 80
1301 Wavre
Boulevard de l'Europe 123-125
1300 Wavre
Active since 1 August 2012
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0445.912.760
- VAT number
- BE 0445.912.760
- Registered office
- Rue du Manil 80, 1301 Wavre
- Names & denominations
- DEPHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 12 December 1991
- Peppol
- Active · Active since 31 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten